vorinostat has been researched along with Soft Tissue Neoplasms in 3 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Soft Tissue Neoplasms: Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A multi-centre, open-label, non-randomised phase II trial to investigate the efficacy and safety of vorinostat in patients with locally advanced or metastatic Soft Tissue Sarcoma failing 1st-line anthracycline-based chemotherapy was initiated." | 9.22 | Vorinostat in refractory soft tissue sarcomas - Results of a multi-centre phase II trial of the German Soft Tissue Sarcoma and Bone Tumour Working Group (AIO). ( Burhenne, J; Egerer, G; Grünwald, V; Hajda, J; Hartmann, JT; Heilig, CE; Ho, AD; Hüsing, J; Kasper, B; Lehmann, L; Mayer, F; Mayer-Steinacker, R; Mechtersheimer, G; Mikus, G; Ottawa, G; Schmitt, T; Schütte, J, 2016) |
| "A multi-centre, open-label, non-randomised phase II trial to investigate the efficacy and safety of vorinostat in patients with locally advanced or metastatic Soft Tissue Sarcoma failing 1st-line anthracycline-based chemotherapy was initiated." | 5.22 | Vorinostat in refractory soft tissue sarcomas - Results of a multi-centre phase II trial of the German Soft Tissue Sarcoma and Bone Tumour Working Group (AIO). ( Burhenne, J; Egerer, G; Grünwald, V; Hajda, J; Hartmann, JT; Heilig, CE; Ho, AD; Hüsing, J; Kasper, B; Lehmann, L; Mayer, F; Mayer-Steinacker, R; Mechtersheimer, G; Mikus, G; Ottawa, G; Schmitt, T; Schütte, J, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ye, S | 1 |
| Lawlor, MA | 1 |
| Rivera-Reyes, A | 1 |
| Egolf, S | 1 |
| Chor, S | 1 |
| Pak, K | 1 |
| Ciotti, GE | 1 |
| Lee, AC | 1 |
| Marino, GE | 1 |
| Shah, J | 1 |
| Niedzwicki, D | 1 |
| Weber, K | 1 |
| Park, PMC | 1 |
| Alam, MZ | 1 |
| Grazioli, A | 1 |
| Haldar, M | 1 |
| Xu, M | 1 |
| Perry, JA | 1 |
| Qi, J | 1 |
| Eisinger-Mathason, TSK | 1 |
| Schmitt, T | 1 |
| Mayer-Steinacker, R | 1 |
| Mayer, F | 1 |
| Grünwald, V | 1 |
| Schütte, J | 1 |
| Hartmann, JT | 1 |
| Kasper, B | 1 |
| Hüsing, J | 1 |
| Hajda, J | 1 |
| Ottawa, G | 1 |
| Mechtersheimer, G | 1 |
| Mikus, G | 1 |
| Burhenne, J | 1 |
| Lehmann, L | 1 |
| Heilig, CE | 1 |
| Ho, AD | 1 |
| Egerer, G | 1 |
| Sampson, ER | 1 |
| Amin, V | 1 |
| Schwarz, EM | 1 |
| O'Keefe, RJ | 1 |
| Rosier, RN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study to Investigate the Efficacy and Tolerability of Vorinostat in Patients Suffering From Advanced, Metastatic Soft Tissue Sarcoma[NCT00918489] | Phase 2 | 40 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for vorinostat and Soft Tissue Neoplasms
| Article | Year |
|---|---|
Vorinostat in refractory soft tissue sarcomas - Results of a multi-centre phase II trial of the German Soft Tissue Sarcoma and Bone Tumour Working Group (AIO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Germany; Humans; Hydroxamic Acids; Ma | 2016 |
2 other studies available for vorinostat and Soft Tissue Neoplasms
| Article | Year |
|---|---|
YAP1-Mediated Suppression of USP31 Enhances NFκB Activity to Promote Sarcomagenesis.
Topics: Adaptor Proteins, Signal Transducing; Angiomotins; Animals; Antineoplastic Agents; Azepines; Cell Cy | 2018 |
The histone deacetylase inhibitor vorinostat selectively sensitizes fibrosarcoma cells to chemotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Fibroblasts; Fibros | 2011 |